However, reductions in oropharynx cancer incidence should be seen among young and middle-aged adults<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Sept. 23, 2021 (HealthDay News) — Current human papillomavirus (HPV) vaccination rates will have a limited effect on the overall incidence of oropharynx cancer (OPC) through 2045 because older individuals who have not yet been vaccinated remain at high risk, according to a study published online Sept. 2 in JAMA Oncology<\/em>.<\/p>\n Yuehan Zhang, from Johns Hopkins University in Baltimore, and colleagues modeled projected expected 2018 to 2045 OPC incidence under scenarios of no HPV vaccination and current levels of HPV vaccination.<\/p>\n The researchers found that under current HPV vaccination rates, between 2018 and 2045, OPC incidence is projected to decrease in younger individuals (36 to 45 years of age: from 1.4 to 0.8 per 100,000 population; 46 to 55 years of age: from 8.7 to 7.2 per 100,000 population) but will continue to increase among older individuals (70 to 83 years of age: from 16.8 to 29.0 per 100,000 population). The association of HPV vaccination with overall OPC incidence through 2045 will only be modestly affected by HPV vaccination (no vaccination versus vaccination: 14.3 versus 13.8 per 100,000 population in 2045). It is estimated that by 2045, a total of 6,334 OPC cases will be prevented with HPV vaccination, with 88.8 percent of the benefit to be seen in younger age groups (\u00e2\u0089\u00a455 years of age).<\/p>\n “These findings forecast a continued shift in the landscape of OPC to an older population,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n